Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

  • Awaiting development
  • GID-TA11626
  • Expected publication date: TBC

34848-Savolitinib-Osimertinib-for-Non-Small-Cell-Lung-Cancer-V1.0-JUL2024-NON-CONF.pdf (nihr.ac.uk)